[
    [
        {
            "time": "",
            "original_text": "研发一哥百济神州遭质疑：去年研发支出48亿远超同行",
            "features": {
                "keywords": [
                    "百济神州",
                    "研发支出",
                    "质疑",
                    "同行对比"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "研发一哥百济神州遭质疑：去年研发支出48亿远超同行",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-09-23",
            "original_text": "格隆汇个股放量排行榜 | 9月23日",
            "features": {
                "keywords": [
                    "个股放量",
                    "排行榜"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "格隆汇个股放量排行榜 | 9月23日",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 6,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "议事厅丨复星医药业绩承压，上半年50亿销售费用侵蚀利润，“医药界PE”下一步该如何破局？ 盈利能力下降",
            "features": {
                "keywords": [
                    "复星医药",
                    "销售费用",
                    "侵蚀利润",
                    "盈利能力下降"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "议事厅丨复星医药业绩承压，上半年50亿销售费用侵蚀利润，“医药界PE”下一步该如何破局？ 盈利能力下降",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "4+7带量采购中标结果明日出炉，中国中药挫逾5%领跌医药股",
            "features": {
                "keywords": [
                    "4+7带量采购",
                    "中标结果",
                    "中国中药",
                    "领跌医药股"
                ],
                "sentiment_score": -0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "4+7带量采购中标结果明日出炉，中国中药挫逾5%领跌医药股",
                "Correlation": 8,
                "Sentiment": 4,
                "Importance": 9,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 9,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2019-09-16至2019-09-22",
            "original_text": "消费+科技属性将驱动医药长牛 —— 医药行业周报（2019.09.16-2019.09.22）",
            "features": {
                "keywords": [
                    "消费+科技",
                    "医药长牛",
                    "行业周报"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "消费+科技属性将驱动医药长牛 —— 医药行业周报（2019.09.16-2019.09.22）",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        },
        {
            "time": "",
            "original_text": "[中信建投医药|行业周报] 新旧交替机会不断 配置高性价比标的",
            "features": {
                "keywords": [
                    "中信建投",
                    "行业周报",
                    "新旧交替",
                    "高性价比标的"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[中信建投医药|行业周报] 新旧交替机会不断 配置高性价比标的",
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "医药行业周报: 我国迎来首仿药上市热潮, 建议关注相关优质企业",
            "features": {
                "keywords": [
                    "医药行业",
                    "首仿药",
                    "上市热潮",
                    "优质企业"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药行业周报: 我国迎来首仿药上市热潮, 建议关注相关优质企业",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        }
    ]
]